The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

Miscommunication between hospital staff regularly puts patients at risk, a new study says. Poor communications between health ...

Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

Healthcare & Pharmaceuticalscategory US CDC advisers begin review of vaccine guidelines after months-long delay 3:43 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Bristol Myers' heart ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered a liver injury.

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $23.00.

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.